Guided Therapeutics Inc (OTCMKTS:GTHP) Issues Update on Start of Clinical Trial for US FDA Approval

Guided Therapeutics Inc (OTCMKTS:GTHP) is best known for having come up with the rapid and painless cervical detection system known as LuViva, which had been developed using its own patented biophotonic technology. Yesterday, the company provided an update with regards to its key clinical trial.

Trading Data

On Monday, GTHP stock moved down 4.17% to $0.2300 with more than 269.99K shares traded, compared to volume of 13.77K shares. The stock moved within a range of $0.1611 – 0.2400 after opening trading at $0.2400.

Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval

The results from the particular study are critical since these results would be used to get approval from the United States Food and Drug Administration. The company has decided to use the services of a number of clinics for the study and the clinics are going to be both community as well as academic ones so as to represent the right population demographics.

Mark Faupel, who is the Chief Executive Officer of the company spoke about the latest developments as well. He noted that the company was highly pleased at the fact that it had managed to engge the services of as many as four clinical centres, who were going to be involved in the enrolment of the patients for the study. He went on to add the fact that two community clinics had been added to the mix was going to help in shortening the timeline for completion.